Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03865082 · ClinicalTrials.gov registry record · Phase 2

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

A Phase 2 study of Solid Tumor, sponsored by Idera Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
3
Study locations

NCT03865082: Active Phase 2 study of Solid Tumor, sponsored by Idera Pharmaceuticals.

NCT03865082 is a Phase 2 study of Solid Tumor that is active but no longer recruiting, run by Idera Pharmaceuticals. The registered enrollment target is 30 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03865082, a Phase 2 study of Solid Tumor, is active but no longer recruiting, sponsored by Idera Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.

Primary Outcome

Efficacy measure by objective response rate

Conditions Studied

Solid Tumor

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Tilsotolimod

Study Locations (3)

Arizona

  • Banner University Medical Center Tucson Campus - Tucson

California

  • University of Southern California/ Hoag Hospital Presbyterian - Newport Beach

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-10-29
Est. Completion 2022-04
Phase Phase 2
Idera Pharmaceuticals

10 total trials

What the registry record for NCT03865082 still lists

NCT03865082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT03865082 reports a single indexed study location in Arizona, California, Texas.

Frequently Asked Questions

What is clinical trial NCT03865082 about?

NCT03865082 is a clinical study titled "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)". A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.

What is the current status of trial NCT03865082?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-29. Estimated completion is 2022-04.

What conditions does trial NCT03865082 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT03865082?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Tilsotolimod (DRUG).

Who is sponsoring clinical trial NCT03865082?

This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03865082 being conducted?

This trial has 3 study locations across Arizona, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03865082's enrollment target sits among peer trials

30 156th of 196 higher than 36 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03865082, the US trial registry maintained by the National Library of Medicine. NCT03865082 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.